Sutro Biopharma Inc. (NASDAQ:STRO) concluded the trading at $7.70 on Wednesday, November 23 with a fall of -3.51% from its closing price on previous day.
Taking a look at stock we notice that its last check on previous day was $7.98 and 5Y monthly beta was reading 0.88 with its price kept floating in the range of $7.20 and $8.155 on the day. Considering stock’s 52-week price range provides that STRO hit a high price of $17.70 and saw its price falling to a low level of $3.33 during that period. Over a period of past 1-month, stock came adding 10.95% in its value.
With its current market valuation of $423.73 million, Sutro Biopharma Inc. is set to declare its quarterly results on Nov 07, 2022 – Nov 14, 2022. Analysts are in estimates of -$0.74 per share for company’s earnings in the current quarter and are expecting its annual EPS growth moving up to -$2.77 for 2022 with estimates of that growing to -$2.96 in next year. These estimates are suggesting current year growth of -21.00% for EPS and -6.90% growth next year.
Analysts watching the company’s growth closely have provided estimates for its revenue growth with an average revenue estimate of $12.68 million. They suggested that in the process company could generate revenue of as low as $5.2 million which could climb up to $17.63 million to hit a high. The average estimate is representing an increase of 41.40% in sales growth from that of posted by the company in the same quarter of last year. In keeping analyst consensus estimate with, company is forecasted to be making an annual revenue of $51.68 million in 2022, which will be -16.50% less from revenue generated by the company last year.
In last 7 days, analysts came adjusting their opinions about stock’s EPS with no upward and no downward revisions, an indication which could give clearer idea about the company’s short term price movement. In contrast, when we review STRO stock’s current outlook then short term indicators are assigning it an average of 100% Buy, while medium term indicators are categorizing the stock at an average of 50% Buy. Long term indicators are suggesting an average of 50% Buy for it.
Digging deeper we become aware of the PEG ratio of the STRO stock which is currently positioned at 0. It further provides that stock’s current price level is 3.49% away from its 20-day simple moving average and is 21.03% off its SMA50. Its relative strength index (RSI) for 14-periods is oscillating at 59.65 while volatility remained at 7.57% over the past week which changes to 7.92% when measuring it over the past month. Beta is valued at 1.00, while measure of average true range or ATR is currently at 0.58.
In comparing Sutro Biopharma Inc. (STRO)’s stock with other industry players reveals that stock’s current price change of -3.51% and that of -54.14% over the past 12 months is in competing position with that of Pfizer Inc. (PFE) which saw its stock price fall by -0.47% in the last trading and went through a decrease of -4.37% in past 12-month trading. Sutro Biopharma Inc. has a P/E ratio of 0 against that of Pfizer Inc.’s 9.27. On the other hand, the S&P 500 Index was up 0.59% in the last trading session while the Dow Jones Industrial closed the session higher at 0.28%.
Having a second look at Sutro Biopharma Inc. (NASDAQ:STRO) provides that stock’s average daily trading volume for 3 months was 358.53K, while it jumped to 0.47 million when we calculate an average volume for past 10 days. Number of outstanding shares of the stock stood at 57.48 million.
The percentage of outstanding shares held by the insiders is 0.10% while it is 91.30% for the institutional holders. The figures also indicate that as of Oct 13, 2022, number of stock’s short shares was 4.14 million which implies a short ratio of 10.22. This shows down a 7.94% of Short Interest in company’s outstanding shares on the day. In October the standing of shares short improved as it was 4.24 million in the previous month. Subtraction of -48.25% by stock’s current price to its year-to-date value in last trading session is likely to be increasing investors’ interest in the stock as it is hinting an extended uptrend.